Cytomegalovirus (CMV) | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2016

The CMV market targets patients with immunodeficiencies, particularly patients receiving solid organ or hematopoietic stem cell transplants. Current therapies have strong antiviral activity but notable side effects, in particular myelotoxicity. These safety issues and a lack of alternative therapies contribute to the substantial unmet need for additional therapeutic options. Several companies are developing novel antivirals, adoptive cell therapies, and therapeutic and prophylactic vaccines to address various aspects of CMV. The anticipated launch of these agents is expected to transform the CMV space and give patients with high unmet need much-needed treatment options.

Login to access report

launch Related Market Assessment Reports